Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Benjamin Trinité
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters - Journal of Translational Medicine
This work involves plasma samples obtained from participants of the KING, KING cohort extension and KING-VAX cohorts (Hospital Germans Trias i Pujol, Badalona, Spain). These are prospective, observational cohorts; no blinding or randomization was applied. The studies were approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol (HUGTiP: PI-20-122, PI-20-217 and PI-21-351 for KING, KING cohort extension and KING-VAX cohorts, respectively).
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection - Communications Medicine
Abstract The ongoing evolution of SARS-CoV-2, particularly through the emergence of new variants, continues to challenge our understanding of immune protection. While antibody levels correlate with protection against earlier variants such as Alpha and Delta, their relationship with Omicron sub-variants remains unclear.
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic
|
Keywords immune memory B cells antibodies humoral immunology SARS-CoV-2 COVID-19 longitudinal cohorts atypical memory B cells Research topic(s) CP: Immunology Introduction Immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is paramount to the remarkable efficacy of mRNA-based vaccines in protecting against infection or severe disease.1 In the current situation of the COVID-19 pandemic, issues of waning immunity and immune escape by emerging variants have compromised...
By Luis M. Molinos-Albert, Rocio Roig Rubio, Rocío Arriaza Rubio, Edwards Pradenas, Celia Arcos Torres, Alfons Jiménez, Mar Canyelles, Marta Vidal, Diana Sánchez Barrios, Silvia Marfil, Anna Ramírez-Morros, Benjamin Trinité, Josep Vidal-Alaball, Pere Santamaria, Luis Izquierdo, Ruth Aguilar, Anna Ruiz-Comellas, Julia Blanco, Carlota Dobaño, Gemma Moncunill, Carla Martín-Pérez, Ester Aparicio
|
Cell Reports
Verified
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
1 SARS, MERS, and SARS-CoV-2 In the first two decades of the present century, three coronaviruses (CoV) emerged that caused severe respiratory infections in humans. SARS-CoV emerged in late 2002 in Guangdong Province, China, and caused severe acute respiratory syndrome (SARS). Another coronavirus, MERS-CoV, emerged in the Middle East in 2012 and caused Middle East Respiratory Syndrome (MERS). While these outbreaks generated concern, none of them developed into a pandemic.
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later
Keywords COVID-19 BA.2.86 cross-recognition Pirola T cells neutralizing antibodies Introduction The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence and dominance of Omicron sublineages.1 Currently (as of July 2024), the Omicron subvariant BA.2.86, also known as ‘Pirola’, and its immediate descendants, are the predominant variants circulating globally, accounting for over 99% of SARS-CoV-2 cases.2 This variant has raised significant concerns...
Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection - Nature Communications
|
Abstract Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels.
By Marco Brustolin, Nuria Pedreno-Lopez, Jordi Rodon, Víctor Urrea, Edwards Pradenas, Anna Pons-Grífols, Carmen Aguilar-Gurrieri, Benjamin Trinité, Jordana Munoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julia Blanco, Victor Guallar, Bonaventura Clotet, Joaquim Segalés Verified
|
Nature
Verified
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models - npj Vaccines
Abstract Age is associated with reduced efficacy of vaccines and linked to higher risk of severe COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant.
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity - Nature Communications
Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA+ memory B cell, with a broad neutralizing activity against former and new SARS-CoV-2 variants, including XBB.1.16 and BA.2.86 Omicron subvariants.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2 - npj Vaccines
Abstract In response to COVID-19 pandemic, we have launched a vaccine development program against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PHH-1V) evaluated in a phase 1-2a dose-escalation, randomized clinical trial conducted in Catalonia, Spain.
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses - npj Vaccines
Abstract Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag.
A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant
Abstract In the present study we report the functional and structural characterization of 17T2, a new highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody (mAb) isolated from a convalescent COVID-19 individual infected during the first wave of the COVID-19 pandemic. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA memory B cell and developed as a human recombinant IgG1.
Stable neutralizing antibody levels six months after mild and severe COVID-19 episode
Highlights • Neutralizing activity against SARS-CoV-2 is maintained for at least 6 months • Anti-RBD and anti-S2 IgG titers show a constant decay • Maintenance of neutralizing activity suggests a potential evolution of the immunity • Hospitalized patients maintain higher neutralizing capacity than non-hospitalized Abstract Background Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development.
Stable neutralizing antibody levels six months after mild and severe COVID-19 episode
New Results View ORCID ProfileEdwards Pradenas, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Ferran Tarrés-Freixas, Silvia Pérez-Yanes, Carla Rovirosa, Erola Ainsua-Enrich, Jordi Rodon, Júlia Vergara-Alert, Joaquim Sagalés, Victor Guallar, Alfonso Valencia, Nuria Izquierdo-Useros, Roger Paredes, Lourdes Mateu, Anna Chamorro, Marta Massanella, Jorge Carrillo, Bonaventura Clotet, View ORCID ProfileJulià Blanco doi:...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Benjamin
Contact Benjamin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack